| Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non–small cell lung cancer patients Z Yang, N Yang, Q Ou, Y Xiang, T Jiang, X Wu, H Bao, X Tong, X Wang, ... Clinical Cancer Research 24 (13), 3097-3107, 2018 | 408 | 2018 |
| Widespread and functional RNA circularization in localized prostate cancer S Chen, V Huang, X Xu, J Livingstone, F Soares, J Jeon, Y Zeng, JT Hua, ... Cell 176 (4), 831-843. e22, 2019 | 343 | 2019 |
| Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation TM Marin, K Keith, B Davies, DA Conner, P Guha, D Kalaitzidis, X Wu, ... The Journal of clinical investigation 121 (3), 1026-1043, 2011 | 289 | 2011 |
| MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation X Wu, J Simpson, JH Hong, KH Kim, NK Thavarajah, PH Backx, BG Neel, ... The Journal of clinical investigation 121 (3), 1009-1025, 2011 | 228 | 2011 |
| Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types Y Shu, X Wu, X Tong, X Wang, Z Chang, Y Mao, X Chen, J Sun, Z Wang, ... Scientific reports 7 (1), 583, 2017 | 183 | 2017 |
| Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer W Fang, Y Ma, JC Yin, S Hong, H Zhou, A Wang, F Wang, H Bao, X Wu, ... Clinical Cancer Research 25 (16), 5015-5026, 2019 | 152 | 2019 |
| Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer DS Wang, ZX Liu, YX Lu, H Bao, X Wu, ZL Zeng, Z Liu, Q Zhao, CY He, ... Gut 68 (7), 1152-1161, 2019 | 147 | 2019 |
| Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer XX Peng, R Yu, X Wu, SY Wu, C Pi, ZH Chen, XC Zhang, CY Gao, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 139 | 2020 |
| Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC K Chen, F Zhou, W Shen, T Jiang, X Wu, X Tong, YW Shao, S Qin, C Zhou Journal of Thoracic Oncology 12 (6), e65-e68, 2017 | 95 | 2017 |
| Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small … H Wang, Q Ou, D Li, T Qin, H Bao, X Hou, K Wang, F Wang, Q Deng, ... Cancer 125 (20), 3535-3544, 2019 | 94 | 2019 |
| Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer SD Bailey, K Desai, KJ Kron, P Mazrooei, NA Sinnott-Armstrong, ... Nature genetics 48 (10), 1260-1266, 2016 | 94 | 2016 |
| Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer L Tong, N Ding, X Tong, J Li, Y Zhang, X Wang, X Xu, M Ye, C Li, X Wu, ... Theranostics 9 (19), 5532, 2019 | 89 | 2019 |
| Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study Y Wang, L Yang, H Bao, X Fan, F Xia, J Wan, L Shen, Y Guan, H Bao, ... PLoS Medicine 18 (8), e1003741, 2021 | 75 | 2021 |
| Oncogenic ras-induced down-regulation of autophagy mediator Beclin-1 is required for malignant transformation of intestinal epithelial cells BH Yoo, X Wu, Y Li, M Haniff, T Sasazuki, S Shirasawa, EL Eskelinen, ... Journal of biological chemistry 285 (8), 5438-5449, 2010 | 65 | 2010 |
| Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib Y Liu, Y Li, Q Ou, X Wu, X Wang, YW Shao, J Ying Lung Cancer 118, 1-5, 2018 | 64 | 2018 |
| Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells Z Liu, H Li, X Wu, BH Yoo, SR Yan, AW Stadnyk, T Sasazuki, S Shirasawa, ... Oncogene 25 (59), 7680-7690, 2006 | 62 | 2006 |
| Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes SY Liu, H Bao, Q Wang, WM Mao, Y Chen, X Tong, ST Xu, L Wu, YC Wei, ... Nature communications 12 (1), 6450, 2021 | 59 | 2021 |
| Adipocyte Enhancer‐Binding Protein 1 Modulates Adiposity and Energy Homeostasis HS Ro, L Zhang, A Majdalawieh, SW Kim, X Wu, PJ Lyons, C Webber, ... Obesity 15 (2), 288-302, 2012 | 57 | 2012 |
| Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer H Xia, X Xue, H Ding, Q Ou, X Wu, M Nagasaka, YW Shao, X Hu, SHI Ou Clinical lung cancer 21 (3), 247-254, 2020 | 56 | 2020 |
| Increased BRAF heterodimerization is the common pathogenic mechanism for Noonan Syndrome-associated RAF1 mutants X Wu, J Yin, J Simpson, KH Kim, S Gu, JH Hong, P Bayliss, PH Backx, ... Molecular and Cellular Biology 32 (19), 3872-3890, 2012 | 53 | 2012 |
Hua BaoGeneseeq Technology Inc.Verified email at geneseeq.com
